NAGE
Niagen Bioscience, Inc.
Key Financials
Gross Profit
$83.2M
↑ 35.1%
Net Income
$17.4M
↑ 103.3%
Operating Income
$16.3M
↑ 110.7%
EPS (Diluted)
$0.20
↑ 81.8%
Total Assets
$106.4M
↑ 55.8%
Total Liabilities
$29.9M
↑ 34.7%
Revenue
$129.4M
↑ 29.9%
Cash & Equivalents
$44.5M
↑ 63.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 3/19/2026 | View on SEC |
| 8-K | 3/4/2026 | View on SEC |
| 10-K | 3/4/2026 | View on SEC |
| 8-K | 2/26/2026 | View on SEC |
| 4 | 2/24/2026 | View on SEC |
| 4 | 2/24/2026 | View on SEC |
| 4 | 2/24/2026 | View on SEC |
| SCHEDULE 13G/A | 1/30/2026 | View on SEC |
| 8-K | 12/22/2025 | View on SEC |
| 4 | 11/17/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NAGE |
| Company Name | Niagen Bioscience, Inc. |
| CIK | 1386570 |
| Sector | Medicinal Chemicals & Botanical Products |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2833 |
| SIC Description | Medicinal Chemicals & Botanical Products |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 310-388-6706 |